Yaron Werber has given his Buy rating due to a combination of factors, primarily the promising progress and outcomes of IO Biotech’s clinical trials. The company’s Phase 3 melanoma study is on ...
The company reported a strong cash position, which is expected to fund operations into late 2026, and emphasized the progress made in its clinical programs, including the completion of enrollment ...
The company's CEO, James Dentzer, expressed optimism about the progress of Curis's clinical programs and the potential of emavusertib, particularly given the durable responses observed in salvage ...
Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus accrued interest totaled approximately $3.7 million. Included in the current ...
These "never words" can be harmful when spoken by clinicians to patients and families facing serious illness. Seriously ill patients and their families experience intense emotional suffering, and ...
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) ("Shuttle Pharma" or the "Company"), a discovery and development stage specialty pharmaceutical ...
A clinical trial involves the study of the safety, efficacy and/or dosage regimen of a therapeutic intervention (such as a drug) in humans selected according to predetermined criteria of ...